OFFICE LEASE KILROY REALTY KILROY AIRPORT CENTER LONG BEACH KILROY REALTY, L.P., a Delaware limited partnership, as Landlord, and DERMAVANT SCIENCES, INC, a Delaware corporation, as Tenant.Office Lease • March 29th, 2019 • Dermavant Sciences LTD • Pharmaceutical preparations • California
This Office Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between KILROY REALTY, L.P., a Delaware limited partnership (“Landlord”), and DERMAVANT SCIENCES INC., a Delaware corporation (“Tenant”).
FIRST AMENDMENT TO FUNDING AGREEMENTFunding Agreement • March 29th, 2019 • Dermavant Sciences LTD • Pharmaceutical preparations
This First Amendment to Funding Agreement (this “Amendment”) is made and entered into as of October 11, 2018 (the “First Amendment Effective Date”), by and between Dermavant Sciences GmbH, a company organized under the laws of Switzerland (“Dermavant”), and NovaQuest Co-Investment Fund VIII, L.P. a limited partnership organized under the laws of Delaware, with a place of business at 4208 Six Forks Road, Suite 920 Raleigh, NC 27609 (“NovaQuest”).
FUNDING AGREEMENTFunding Agreement • March 29th, 2019 • Dermavant Sciences LTD • Pharmaceutical preparations • New York
This Funding Agreement (this “Agreement”) is entered into as of July 10, 2018 (the “Effective Date”), between Dermavant Sciences GmbH, a company organized under the laws of Switzerland (“Dermavant”), and NovaQuest Co-Investment Fund VIII, L.P. a limited partnership organized under the laws of Delaware, with a place of business at 4208 Six Forks Road, Suite 920 Raleigh, NC 27609 (“NovaQuest”). Dermavant and NovaQuest are each referred to herein by name or, individually, as a “Party” or, collectively, as “Parties.”
DERMAVANT SCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • March 29th, 2019 • Dermavant Sciences LTD • Pharmaceutical preparations • New York
This Employment Agreement (this “Agreement”) is entered into as of March 18, 2019, by and between Cyril Allouche (the “Executive”) and Dermavant Sciences, Inc. (the “Company”).
